256 related articles for article (PubMed ID: 22941380)
1. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.
Stern M; Passweg JR; Meyer-Monard S; Esser R; Tonn T; Soerensen J; Paulussen M; Gratwohl A; Klingebiel T; Bader P; Tichelli A; Schwabe D; Koehl U
Bone Marrow Transplant; 2013 Mar; 48(3):433-8. PubMed ID: 22941380
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
4. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
Passweg JR; Koehl U; Uharek L; Meyer-Monard S; Tichelli A
Best Pract Res Clin Haematol; 2006; 19(4):811-24. PubMed ID: 16997185
[TBL] [Abstract][Full Text] [Related]
5. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
6. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
Ruggeri L; Mancusi A; Burchielli E; Capanni M; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2008; 40(1):84-90. PubMed ID: 17964828
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells and tumor control.
Cooley S; Weisdorf DS
Curr Opin Hematol; 2010 Nov; 17(6):514-21. PubMed ID: 20827184
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
11. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.
Nguyen S; Béziat V; Norol F; Uzunov M; Trebeden-Negre H; Azar N; Boudifa A; Bories D; Debré P; Vernant JP; Vieillard V; Dhédin N
Transfusion; 2011 Aug; 51(8):1769-78. PubMed ID: 21332732
[TBL] [Abstract][Full Text] [Related]
12. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
[TBL] [Abstract][Full Text] [Related]
13. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
[TBL] [Abstract][Full Text] [Related]
14. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects.
Lang P; Pfeiffer M; Müller I; Schumm M; Ebinger M; Koscielniak E; Feuchtinger T; Föll J; Martin D; Handgretinger R
Klin Padiatr; 2006; 218(6):321-6. PubMed ID: 17080334
[TBL] [Abstract][Full Text] [Related]
15. Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation.
Meyer-Monard S; Passweg J; Siegler U; Kalberer C; Koehl U; Rovó A; Halter J; Stern M; Heim D; Alois Gratwohl JR; Tichelli A
Transfusion; 2009 Feb; 49(2):362-71. PubMed ID: 19389215
[TBL] [Abstract][Full Text] [Related]
16. [Donor peripheral hematopoietic stem cells infusion for prophylaxis of relapse of high risk leukemia after allogeneic hematopoietic stem cell transplantation].
Liu DH; Huang XJ; Chen H; Xu LP; Liu KY; Han W; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):6-9. PubMed ID: 16732930
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell alloreactivity 10 years later.
Velardi A
Curr Opin Hematol; 2012 Nov; 19(6):421-6. PubMed ID: 22954728
[TBL] [Abstract][Full Text] [Related]
18. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
[TBL] [Abstract][Full Text] [Related]
19. Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia.
Pérez-Martínez A; González-Vicent M; Valentín J; Aleo E; Lassaletta A; Sevilla J; Vicario JL; Ramírez M; Díaz MA
Bone Marrow Transplant; 2012 Nov; 47(11):1419-27. PubMed ID: 22410752
[TBL] [Abstract][Full Text] [Related]
20. The role of natural killer cells in hematopoietic stem cell transplantation.
Tsirigotis PD; Resnick IB; Shapira MY
Ann Med; 2012 Mar; 44(2):130-45. PubMed ID: 21410396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
